Compare Mesoblast Limited (MESO) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $236.98 (market cap $44.37B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 20.4× Mesoblast Limited's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | TTWO | |
|---|---|---|
Market Cap | $2.17B | $44.37B |
Sector | Technology | Media |
52-Week High | $20.96 | $262.29 |
52-Week Low | $12.88 | $189.69 |
Enterprise Value | $2.17B | $45.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Take-Two Interactive (TTWO) trades at $239.04, up 1.0% on the day, with a bullish technical outlook as the price approaches resistance near $240. The company reported three consecutive quarterly EPS beats but posted a net loss of -$4.48B in FY2025, with revenue growth to $5.63B. Investor focus remains on the upcoming Grand Theft Auto VI release, driving positive sentiment despite recent profitability challenges.
The stock offers significant upside to the consensus price target of $302.50, supported by strong analyst buy ratings (78.95%), but carries risks from high debt levels and negative margins. Near-term catalysts include Q2 2026 earnings on August 7, 2026, though execution on GTA VI and cost management are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
